Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHANK-101 in Recurrent Glioblastoma
NCT07831161Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of CBT101 in glioblastoma (GBM). Primary endpoint: Progression-Free Survival at 48 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
CBT101
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07831161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07831161.